新型冠状病毒感染相关儿童多系统炎症综合征与细胞因子风暴

doi:10.11958/20220587

天津医药 ›› 2022, Vol. 50 ›› Issue (12): 1340-1344.doi: 10.11958/20220587

• 综述 • 上一篇

新型冠状病毒感染相关儿童多系统炎症综合征与细胞因子风暴

崔亚琼¹^,²(), 刘薇¹^,^△()

1 天津市儿童医院、天津大学儿童医院（邮编300134）
2 天津市儿科研究所、天津市儿童出生缺陷防治重点实验室

收稿日期:2022-04-17 修回日期:2022-06-28 出版日期:2022-12-15 发布日期:2022-12-30
通讯作者: 刘薇 E-mail:cuiyaqiong2012@163.com;lance_1971@163.com
作者简介:崔亚琼（1990），女，研究实习员，主要从事临床检验、儿童遗传代谢病等方面研究。E-mail：cuiyaqiong2012@163.com
基金资助:
天津市自然科学基金重点项目(20JCZDJC00660)

COVID-19 infection-associated multisystem inflammatory syndrome and cytokine storms in children

CUI Yaqiong¹^,²(), LIU Wei¹^,^△()

1 Tianjin Children's Hospital (Children's Hospital of Tianjin University), Tianjin 300134, China
2 Tianjin Pediatric Research Institute, Tianjin Key Laboratory of Birth Defects for Prevention and Treatment

Received:2022-04-17 Revised:2022-06-28 Published:2022-12-15 Online:2022-12-30
Contact: LIU Wei E-mail:cuiyaqiong2012@163.com;lance_1971@163.com

崔亚琼, 刘薇. 新型冠状病毒感染相关儿童多系统炎症综合征与细胞因子风暴[J]. 天津医药, 2022, 50(12): 1340-1344.

CUI Yaqiong, LIU Wei. COVID-19 infection-associated multisystem inflammatory syndrome and cytokine storms in children[J]. Tianjin Medical Journal, 2022, 50(12): 1340-1344.

摘要/Abstract

摘要：

儿童多系统炎症综合征（MIS-C）是一种合并多器官功能受损的全身炎症综合征，大多数患儿存在新型冠状病毒（SARS-CoV-2）感染证据或新型冠状病毒肺炎（COVID-19）患者接触史。患儿常出现发热、胃肠道症状、心功能异常及休克等表现。细胞因子风暴（CS）是由外界刺激触发的全身性炎症反应，引起CS的诱因包括医源性、病源性、单基因或自身免疫性疾病等。MIS-C发病机制尚未完全明确，可能与SARS-CoV-2感染后引起的机体过度免疫反应有关。就COVID-19感染相关MIS-C的临床特征和CS的发生及诱因予以综述，并讨论两者间的关系，以期为MIS-C的机制研究和临床诊断提供参考。

关键词: 冠状病毒感染, 儿童, 新型冠状病毒肺炎, 儿童多系统炎症综合征, 细胞因子风暴

Abstract:

Multisystem inflammatory syndrome in children (MIS-C) is a systemic inflammatory syndrome with multi-organ dysfunctions. Most of the children have evidence of severe acute respiratory syndrome-associated coronavirus (SARS-CoV-2) infection or a history of exposure to patients with coronavirus disease 2019 (COVID-19). Children often present with fever, gastrointestinal symptoms, cardiac dysfunctions, shock and other multi-system symptoms. Cytokine storm (CS) is an inflammatory response triggered by external stimulations. Factors causing CS include iatrogenic, pathogenic, monogenic or autoimmune diseases. The pathogenesis of MIS-C is still unclear, which may be related to the over-response of immune system caused by SARS-CoV-2 infections. In this paper, the clinical characteristics of COVID-19 infection-related MIS-C are summarized, and the relationship between MIS-C and CS is discussed, aiming to provide references for the mechanistic investigation and clinical diagnosis of MIS-C.

Key words: coronavirus infections, child, COVID-19, multisystem inflammatory syndrome in children, cytokine storm

中图分类号:

R725.1

参考文献 51

[1]	CASTAGNOLI R, VOTTO M, LICARI A, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents:A systematic review[J]. JAMA Pediatr, 2020, 174(9):882-889. doi:10.1001/jamapediatrics.2020.1467.
[2]	DONG Y, MO X, HU Y, et al. Epidemiology of COVID-19 among children in China[J]. Pediatrics, 2020, 145(6):e20200702. doi:10.1542/peds.2020-0702.
[3]	NAKRA N A, BLUMBERG D A, HERRERA-GUERRA A, et al. Multi-system inflammatory syndrome in children (MIS-C) following SARS-CoV-2 infection:Review of clinical presentation,hypothetical pathogenesis,and proposed management[J]. Children(Basel), 2020, 7(7):69. doi:10.3390/children7070069.
[4]	FUNK A L, FLORIN T A, KUPPERMANN N, et al. Outcomes of SARS-CoV-2-positive youths tested in emergency departments:The Global PERN-COVID-19 Study[J]. JAMA Netw Open, 2022, 5(1):e2142322. doi:10.1001/jamanetworkopen.2021.42322.
[5]	WHITTAKER E, BAMFORD A, KENNY J, et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2[J]. JAMA, 2020, 324(3):259-269. doi:10.1001/jama.2020.10369.
[6]	BELHADJER Z, MÉOT M, BAJOLLE F, et al. Acute heart failure in multisystem inflammatory syndrome in children in the context of global SARS-CoV-2 pandemic[J]. Circulation, 2020, 142(5):429-436. doi:10.1161/CIRCULATIONAHA.120.048360.
[7]	TOUBIANA J, POIRAULT C, CORSIA A, et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris,France:prospective observational study[J]. BMJ, 2020, 369: m2094. doi:10.1136/bmj.m2094.
[8]	KWAK J H, LEE S Y, CHOI J W. Clinical features,diagnosis,and outcomes of multisystem inflammatory syndrome in children associated with coronavirus disease 2019[J]. Clin Exp Pediatr, 2021, 64(2):68-75. doi:10.3345/cep.2020.01900.
[9]	YANG X, YU Y, XU J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan,China:a single-centered, retrospective, observational study[J]. Lancet Respir Med, 2020, 8(5):475-481. doi:10.1016/s2213-2600(20)30079-5.
[10]	ROTHAN H A, BYRAREDDY S N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak[J]. J Autoimmun, 2020, 109:102433. doi:10.1016/j.jaut.2020.102433.
[11]	TISONCIK J R, KORTH M J, SIMMONS C P, et al. Into the eye of the cytokine storm[J]. Microbiol Mol Biol Rev, 2012, 76(1):16-32. doi:10.1128/MMBR.05015-11.
[12]	YANG M C, TSAI C C, SU Y T, et al. The emergence of a new cytokine storm during the COVID-19 pandemic:Multisystem inflammatory syndrome in children[J]. Kaohsiung J Med Sci, 2021, 37(3):255-256. doi:10.1002/kjm2.12347.
[13]	KAUSHIK A, GUPTA S, SOOD M, et al. A systematic review of multisystem inflammatory syndrome in children associated with SARS-CoV-2 infection[J]. Pediatr Infect Dis J, 2020, 39(11):e340-e346. doi:10.1097/INF.0000000000002888.
[14]	RADIA T, WILLIAMS N, AGRAWAL P, et al. Multi-system inflammatory syndrome in children & adolescents (MIS-C):A systematic review of clinical features and presentation[J]. Paediatr Respir Rev, 2021, 38:51-57. doi:10.1016/j.prrv.2020.08.001.
[15]	JIANG L, TANG K, LEVIN M, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents[J]. Lancet Infect Dis, 2020, 20(11):e276 -e288. doi:10.1016/s1473-3099(20)30651-4.
[16]	MAGBOUL S, KHALIL A, HASSAN M, et al. Multisystem inflammatory syndrome in children(MIS-C)related to COVID-19 infection in the state of Qatar:Association with Kawasaki-like Illness[J]. Acta Biomed, 2022, 92(6):e2021543. doi:10.23750/abm.v92i6.11991.
[17]	MOREEWS M, LE GOUGE K, KHALDI-PLASSART S, et al. Polyclonal expansion of TCR Vbeta 21.3(+) CD4(+) and CD8(+) T cells is a hallmark of multisystem inflammatory syndrome in Children[J]. Sci Immunol, 2021, 6(59):eabh1516. doi:10.1126/sciimmunol.abh1516.
[18]	PIERCE C A, PRESTON-HURLBURT P, DAI Y, et al. Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients[J]. Sci Transl Med, 2020, 12(564):eabd5487. doi:10.1126/scitranslmed.abd5487.
[19]	CARTER M J, SHANKAR-HARI M, TIBBY S M. Paediatric inflammatory multisystem syndrome temporally-associated with SARS-CoV-2 infection:An overview[J]. Intensive Care Med, 2021, 47(1):90-93. doi:10.1007/s00134-020-06273-2.
[20]	AHMED M, ADVANI S, MOREIRA A, et al. Multisystem inflammatory syndrome in children:A systematic review[J]. EClinicalMedicine, 2020, 26:100527. doi:10.1016/j.eclinm.2020.100527.
[21]	PAWAR R S, AKHELIKAR N S, KURANE A B. Acute severe heart failure in a child with congenital heart defect and multisystem inflammatory syndrome in children (MIS-C)[J]. Indian Pediatr, 2021, 58(10):996-997. doi:10.1007/s13312-021-2341-0.
[22]	FELDSTEIN L R, ROSE E B, HORWITZ S M, et al. Multisystem inflammatory syndrome in U.S. children and adolescents[J]. N Engl J Med, 2020, 383(4):334-346. doi:10.1056/NEJMoa2021680.
[23]	SHARMA C, GANIGARA M, GALEOTTI C, et al. Multisystem inflammatory syndrome in children and Kawasaki disease:A critical comparison[J]. Nat Rev Rheumatol, 2021, 17(12):731-748. doi:10.1038/s41584-021-00709-9.
[24]	LIN M T, WU M H. The global epidemiology of Kawasaki disease:Review and future perspectives[J]. Glob Cardiol Sci Pract, 2017, 2017(3): e201720. doi:10.21542/gcsp.2017.20.
[25]	张莉, 雷亚茹, 石瑜, 等. 儿童多系统炎症综合征研究进展[J]. 传染病信息, 2021, 34(4):291-295.
	ZHANG L, LEI Y R, SHI Y, et al. Research progress in multisystem inflammatory syndrome in children[J]. Infect Dis Info, 2021, 34(4):291-295. doi:10.3969/j.issn.1007-8134.2021.04.002.
[26]	RAFFERTY M S, BURROWS H, JOSEPH J P, et al. Multisystem inflammatory syndrome in children (MIS-C) and the coronavirus pandemic:Current knowledge and implications for public health[J]. J Infect Public Health, 2021, 14(4):484-494. doi:10.1016/j.jiph.2021.01.008.
[27]	ZUO Y, YALAVARTHI S, SHI H, et al. Neutrophil extracellular traps in COVID-19[J]. JCI Insight, 2020, 5(11):e138999. doi:10.1172/jci.insight.138999.
[28]	MIDDLETON E A, HE X Y, DENORME F, et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome[J]. Blood, 2020, 136(10):1169-1179. doi:10.1182/blood.2020007008.
[29]	BLONDIAUX E, PARISOT P, REDHEUIL A, et al. Cardiac MRI in children with multisystem inflammatory syndrome associated with COVID-19[J]. Radiology, 2020, 297(3):E283-E288. doi:10.1148/radiol.2020202288.
[30]	GAITONDE M, ZIEBELL D, KELLEMAN M S, et al. COVID-19-related multisystem inflammatory syndrome in children affects left ventricular function and global strain compared with Kawasaki disease[J]. J Am Soc Echocardiogr, 2020, 33(10):1285-1287. doi:10.1016/j.echo.2020.07.019.
[31]	DIORIO C, HENRICKSON S E, VELLA L A, et al. Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2[J]. J Clin Invest, 2020, 130(11):5967-5975. doi:10.1172/JCI140970.
[32]	ABRAMS J Y, OSTER M E, GODFRED-CATO S E, et al. Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA:a retrospective surveillance study[J]. Lancet Child Adolesc Health, 2021, 5(5):323-331. doi:10.1016/s2352-4642(21)00050-x.
[33]	OULDALI N, YANG D D, MADHI F, et al. Factors associated with severe SARS-CoV-2 infection[J]. Pediatrics, 2021, 147(3):e2020023432. doi:10.1542/peds.2020-023432.
[34]	YE Q, WANG B, MAO J. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19[J]. J Infect, 2020, 80(6):607-613. doi:10.1016/j.jinf.2020.03.037.
[35]	DOLINGER M T, PERSON H, SMITH R, et al. Pediatric Crohn disease and multisystem inflammatory syndrome in children (MIS-C) and COVID-19 treated with infliximab[J]. J Pediatr Gastroenterol Nutr, 2020, 71(2):153-155. doi:10.1097/MPG.0000000000002809.
[36]	FAJGENBAUM D C, JUNE C H. Cytokine Storm[J]. N Engl J Med, 2020, 383(23):2255-2273. doi:10.1056/NEJMra2026131.
[37]	GRUPP S A, KALOS M, BARRETT D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia[J]. N Engl J Med, 2013, 368(16):1509-1518. doi:10.1056/NEJMoa1215134.
[38]	王玉亮, 王峰, 耿洁. 细胞因子与细胞因子风暴[J]. 天津医药, 2020, 48(6):494-499.
	WANG Y L, WAN F, GENG J. Cytokine and cytokine storm[J]. Tianjin Med J, 2020, 48(6):494-499. doi:10.11958/20200323.
[39]	刘爱良, 鲍燕敏, 郑跃杰, 等. 呼吸道病毒感染相关细胞因子风暴与靶向治疗策略[J]. 中华实用儿科临床杂志, 2021, 36(24):1913-1917.
	LIU A L, BAO Y M, ZHENG Y J, et al. Cytokine storms associated with respiratory virus infection and targeted therapy strategies[J]. Chin J Appl Clin Pediatr, 2021, 36(24):1913-1917. doi:10.3760/cma.j.cn101070-20210809-00943.
[40]	KARKI R, KANNEGANTI T D. The 'cytokine storm':molecular mechanisms and therapeutic prospects[J]. Trends Immunol, 2021, 42(8):681-705. doi:10.1016/j.it.2021.06.001.
[41]	GODFRED-CATO S, BRYANT B, LEUNG J, et al. COVID-19-associated multisystem inflammatory syndrome in children-United States,March-July 2020[J]. MMWR Morb Mortal Wkly Rep, 2020, 69(32):1074-1080. doi:10.15585/mmwr.mm6932e2.
[42]	PARK A, IWASAKI A. Type Ⅰ and type Ⅲ interferons-induction, signaling,evasion,and application to combat COVID-19[J]. Cell Host Microbe, 2020, 27(6):870-878. doi:10.1016/j.chom.2020.05.008.
[43]	安纪红. 感染与细胞因子风暴[J]. 中华实验和临床感染病杂志(电子版), 2013, 7(6):925-926.
	AN J H. Infection and cytokine storms[J]. Chin J Exp Clin Infect Dis (Electronic Edition),2013, 7(6):925-926. doi:10.3877/cma.j.issn.1674-1358.2013.06.035.
[44]	CHEN G, WU D, GUO W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019[J]. J Clin Invest, 2020, 130(5):2620-2629. doi:10.1172/JCI137244.
[45]	冯志冠, 鲍燕敏, 杨永弘, 等. 新型冠状病毒感染相关儿童多系统炎症综合征[J]. 中华实用儿科临床杂志, 2020, 35(15):1121-1124.
	FENG Z G, BAO Y M, YANG Y H, et al. Multisystem inflammatory syndrome in children related with 2019 Novel Coronavirus infection[J]. Chin J Appl Clin Pediatr, 2020, 35(15):1121-1124. doi:10.3760/cma.j.cn101070-20200710-01156.
[46]	HU K, GUAN W J, BI Y, et al. Efficacy and safety of Lianhuaqingwen capsules,a repurposed Chinese herb,in patients with coronavirus disease 2019:A multicenter,prospective,randomized controlled trial[J]. Phytomedicine, 2021, 85:153242. doi:10.1016/j.phymed.2020.153242.
[47]	CHEN Y, LIU C, WANG T, et al. Efficacy and safety of Bufei Huoxue capsules in the management of convalescent patients with COVID-19 infection:A multicentre,double-blind, and randomised controlled trial[J]. J Ethnopharmacol, 2022, 284:114830. doi:10.1016/j.jep.2021.114830.
[48]	ZHANG L, ZHENG X, BAI X, et al. Association between use of Qingfei Paidu Tang and mortality in hospitalized patients with COVID-19:A national retrospective registry study[J]. Phytomedicine, 2021, 85:153531. doi:10.1016/j.phymed.2021.153531.
[49]	CHEN X, FENG Y, SHEN X, et al. Anti-sepsis protection of Xuebijing injection is mediated by differential regulation of pro- and anti-inflammatory Th17 and T regulatory cells in a murine model of polymicrobial sepsis[J]. J Ethnopharmacol, 2018, 211:358-365. doi:10.1016/j.jep.2017.10.001.
[50]	YANG R, LIU H, BAI C, et al. Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19):In silico and experimental study[J]. Pharmacol Res, 2020, 157:104820. doi:10.1016/j.phrs.2020.104820.
[51]	池里群, 周彬, 高文远, 等. 治疗类风湿性关节炎常用药物的研究进展[J]. 中国中药杂志, 2014, 39(15):2851-2858.
	CHI L Q, ZHOU B, GAO W Y, et al. Research progress of drugs commonly used to anti-rheumatoid arthritis[J]. China Journal of Chinese Materia Medica, 2014, 39(15):2851-2858. doi:10.4268/cjcmm20141512.

新型冠状病毒感染相关儿童多系统炎症综合征与细胞因子风暴

COVID-19 infection-associated multisystem inflammatory syndrome and cytokine storms in children

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

参考文献 51

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨敏, 潘艳莎, 张长玲, 陈红英, 郭渠莲, 刘文君. 儿童急性淋巴细胞白血病基线数据及早期治疗反应与预后的相关性[J]. 天津医药, 2024, 52(9): 954-958.
[2]	白梦刻, 杨晓青, 李航, 王龙, 马继伟. 过敏性紫癜肾炎伴新月体形成患儿的实验室指标和病理特征分析[J]. 天津医药, 2024, 52(8): 820-824.
[3]	祁福敏, 苏睿, 郝剑, 苏丽, 范倩, 李昕, 魏蔚. 显微镜下多血管炎相关间质性肺病合并COVID-19患者疫苗保护作用初探[J]. 天津医药, 2024, 52(7): 683-686.
[4]	吕梦娜, 李建斌, 吴锐. 自身炎症性疾病患者合并COVID-19严重程度的早期预测指标探讨[J]. 天津医药, 2024, 52(5): 528-531.
[5]	周洁雯, 马丙南, 区静怡. 儿童鼠伤寒沙门菌肠炎细菌耐药性变迁及治疗分析[J]. 天津医药, 2024, 52(12): 1282-1285.
[6]	姚茜, 王晶, 程娜. 神曲消食口服液治疗小儿轮状病毒感染性腹泻的疗效观察[J]. 天津医药, 2024, 52(12): 1296-1300.
[7]	尼加提·阿力木, 马士凤, 夏木斯娅·阿里木江, 张静, 郑荣秀. 儿童糖尿病合并尿路感染的临床特征及危险因素分析[J]. 天津医药, 2024, 52(10): 1051-1055.
[8]	杨文珊, 盛玉, 陈秀利, 陈吉. 小儿急性胰腺炎序贯化营养支持与肠外营养支持的疗效比较[J]. 天津医药, 2024, 52(10): 1061-1064.
[9]	陈韦, 赵梦雅, 肖飞, 刘传合. 5~17岁儿童百日咳的肺功能改变[J]. 天津医药, 2024, 52(10): 1075-1079.
[10]	薛建铭, 孙硕, 郭云飞, 李晓敏, 李建玲. 艾司氯胺酮对学龄前扁桃体切除患儿术后不良行为改变的影响[J]. 天津医药, 2023, 51(9): 1002-1006.
[11]	胡明月, 李鑫, 高磊, 关明杰. 蒙古黄芪皂苷对铅暴露致发育期大鼠神经炎症与肠道菌群紊乱的影响[J]. 天津医药, 2023, 51(9): 955-960.
[12]	谷松涛, 贾玮, 李月川, 张冬睿, 张雅婷, 高淑连, 李娜. COVID-19合并肺血栓栓塞症的临床特点[J]. 天津医药, 2023, 51(8): 873-877.
[13]	张萌, 覃道锐, 杨博, 谢敏, 刘云飞, 苏鹏. 氢吗啡酮复合罗哌卡因骶管阻滞在儿童尿道下裂手术中的应用效果[J]. 天津医药, 2023, 51(3): 274-276.
[14]	钟慕贤, 谢新荣. 糖尿病酮症酸中毒合并新型冠状病毒肺炎的临床特征分析[J]. 天津医药, 2023, 51(12): 1378-1381.
[15]	王荧荧. 儿童过敏性鼻炎舌下免疫治疗的效果分析及显效时间判断[J]. 天津医药, 2023, 51(11): 1255-1257.